At X-Tosis, we are pioneering the future of neurodegenerative disease treatment by targeting one of the most fundamental drivers of cellular decline: mitochondrial dysfunction. Our innovative compound, XTS, works by inhibiting VDAC1 oligomerization—an essential mechanism in the cascade of cell death, inflammation, and neurological damage seen across multiple neurodegenerative conditions.
By restoring mitochondrial integrity and protecting cells from early dysfunction, we aim not to manage symptoms but to change the trajectory of these diseases entirely.
Our mission is bold and clear: to stop neurodegeneration at its source.
Company Details
- Employees
- 4
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Engineer jobs.
X-Tosis Questions
X-Tosis's LinkedIn profile is https://www.linkedin.com/company/x-tosis
X-Tosis has
4 employees.
View email and phone details for 4
employees at X-Tosis.
X-Tosis's industry is
Biotechnology Research
X-Tosis's top competitors are
Betterbrain,
8400 The Health Network,
Numiera Therapeutics,
Enzymofit,
Ngroup,
Gemma Biotherapeutics,
Protekt Therapeutics,
Guosa Life Sciences,
Tern Therapeutics,
Franklin Biolabs.
X-Tosis's categories are Biotechnology Research
X-Tosis's founding year is 2024
